A jellyfish can close a wound in real time, without stitches, scabs, or scars, a fascinating—and borderline miraculous—healing ability that has long perplexed scientists. 

Now, a new study in Molecular Biology of the Cell has finally revealed the secrets behind this process, identifying two cellular structures that act in a specific sequence.

Jocelyn Malamy, an associate professor at the University of Chicago, first observed this process a decade ago at the Marine Biological Laboratory. Using transparent, dime-sized jellyfish called Clytia hemisphaerica, she watched individual cells move toward each other to close a gap in the tissue.

Now, with colleagues Maxwell Sassaman and Manjula P. Mony, she has mapped the steps of this process and explored its broader significance.

A Flower That Never Stops Blooming

The free-swimming medusa most people picture when they hear “jellyfish” is only one phase of Clytia‘s life. It spends most of its life as a polyp colony attached to rocks, docks, or leaves, and it periodically produces medusae, much like a shrub produces flowers. While medusae live for only a few months, the polyp colonies can persist for much longer.

Clytia medusae are known for their ability to heal quickly. Small wounds close in minutes, and even larger injuries seal in under an hour, all without forming scar tissue. Malamy notes that this type of healing is similar to the scar-free repair seen in embryos.

Since Clytia are transparent, heal rapidly, and lack the immune-mediated inflammation that complicates wound healing in mammals, they serve as an excellent model organism. Scientists can watch epithelial cells close wounds in real time, without interference from scarring or immune reactions. The mechanisms uncovered in Clytia are likely relevant across many animals.

“A lot of the processes that we see in Clytia‘s wound healing are really similar to what you see in all other systems, including mammalian systems,” Malamy explains. “When you’re staring at these epithelial cells, you wouldn’t know this was a jellyfish.”

Two Structures, One Decision Tree

Epithelial cells form the surfaces of the body, including skin, the gut, and internal membranes, and must repair themselves after injury. Malamy previously described Clytia’s wound repair in 2017 and 2018. The new study addresses a longstanding question in epithelial wound healing: do wounds close by cells moving over the gap, or by an actin cable contracting to seal it? The findings show that both mechanisms operate in a specific sequence, with the basement membrane beneath the cells coordinating the transition between them.

The initial response involves lamellipodia, actin-rich extensions that move across the basement membrane, the protein layer beneath all epithelial tissues. These structures pull their parent cells forward to close the wound. Malamy’s team observed lamellipodia forming even in very small wounds within a single cell, a previously undocumented detail.

After the lamellipodia advance, an actomyosin cable forms and contracts after it covers the basement membrane. If damage or debris blocks the membrane, the cable closes the wound and removes debris that lamellipodia cannot cross.

For larger wounds, a third response occurs. When the gap is too wide for lamellipodia to bridge, regardless of how far the cells extend, the entire epithelial sheet lifts and migrates as a unit. Once lamellipodia from opposing edges meet, the same closing sequence resumes.

“This is a truly elegant mechanism where the system can rapidly adapt to heal all the kinds of wounds that might occur in nature,” Malamy says.

What’s Still Unrepaired

If epithelial repair mechanisms are conserved across animal evolution, as current evidence suggests, studies of jellyfish could reveal wound-healing processes that inflammation and scar formation obscure in mammals, making those processes difficult to observe directly.

Researchers have not yet fully understood the basement membrane, which coordinates these processes, and it remains the least understood aspect of wound repair. Scientists still do not know how organisms repair the basement membrane itself.

“It’s great that you can heal a wound by dragging the cells over it,” Malamy says, “but at some point, a damaged basement membrane has to get fixed.” That’s her next target.

Austin Burgess is a writer and researcher with a background in sales, marketing, and data analytics. He holds an MBA, a Bachelor of Science in Business Administration, and a data analytics certification. His work focuses on breaking scientific developments, with an emphasis on emerging biology, cognitive neuroscience, and archaeological discoveries.

A groundbreaking discovery at the University of California, Los Angeles (UCLA) has unveiled a promising new therapeutic avenue for kidney regeneration, leveraging a drug initially designed to repair heart tissue following myocardial infarction. This drug, known as AD-NP1, targets a specific protein—ENPP1—that plays a critical role in impeding the body’s natural healing processes in injured tissues. The revelation that AD-NP1 can also accelerate kidney repair heralds a significant advancement in regenerative medicine, especially for patients suffering from chronic kidney disease (CKD), a condition that affects millions globally.

The heart of this research revolves around a protein named ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). When tissues such as the heart or kidney sustain injury, ENPP1 production escalates, initiating a cascade of metabolic disturbances that hinder energy synthesis within cells. This disruption compromises cellular function and ultimately stalls effective tissue regeneration. In the context of the kidney, which is vital for maintaining systemic homeostasis, such impediments can lead to progressive scarring and functional decline, culminating in kidney failure.

Through years of meticulous experiments, the UCLA team delineated the detrimental impact of ENPP1 on the kidney’s reparative capacity. They observed that injured renal tissue upregulates ENPP1 expression, which in turn resets the metabolic landscape of cells in the damaged microenvironment. This altered metabolic signaling disrupts mitochondrial function, thereby curtailing ATP production essential for cell proliferation and repair. By employing genetic knockout models in mice, where ENPP1 expression was inhibited, the researchers documented a striking enhancement in renal recovery post-injury. These mice demonstrated reduced fibrotic scarring and improved renal biomarkers, signaling restored kidney function.

Central to translating these findings into potential clinical interventions is AD-NP1, a sophisticated monoclonal antibody engineered to specifically neutralize ENPP1. Unlike broad-spectrum immunosuppressants or anti-inflammatory agents, AD-NP1 offers targeted therapeutic precision by binding solely to human ENPP1, circumventing off-target effects. Initially conceptualized to mitigate cardiac fibrosis and promote myocardial regeneration following heart attacks, AD-NP1’s mechanism exerts a similar rejuvenating influence on kidney tissues. The antibody effectively halts the ENPP1-induced metabolic sabotage, facilitating an environment conducive to cellular proliferation and tissue repair.

In experimental paradigms, the administration of AD-NP1 in mice subjected to nephrotoxic diets and chemically induced renal injuries yielded compelling outcomes. Within merely seven days of treatment, subjects exhibited marked improvements in kidney function tests and histological assessments showed diminished collagen deposition and scarring. These findings underscore the drug’s potential to transform the management of acute and chronic kidney injuries by reinstating the organ’s intrinsic regenerative programs, which are often stifled in disease states.

Moreover, the team’s translational approach integrated analyses of human kidney biopsies acquired from individuals with chronic kidney disease. These samples consistently manifested elevated ENPP1 levels relative to healthy controls, substantiating the protein’s pathological role in human renal disorders. This correlation not only reinforces the relevance of the preclinical models used but also paves the way for clinical evaluation of AD-NP1’s efficacy in human subjects suffering from renal ailments.

The broader implications of this discovery extend into the metabolic regulation of tissue repair. ENPP1’s role appears multifaceted, orchestrating cellular energy dynamics and intercellular communication networks that dictate regenerative outcomes. Inhibiting this protein intervenes in maladaptive signaling cascades, thereby restoring bioenergetic balance and enabling clonal expansion of healthy cells adjacent to injury sites. This paradigm shift in understanding organ regeneration emphasizes metabolic modulation as a cornerstone of effective healing strategies.

Prior to this research, the therapeutic targeting of ENPP1 was primarily confined to cardiac medicine. The successful repurposing of AD-NP1 for kidney injury illustrates the concept of cross-organ regenerative mechanisms, where molecular pathways governing tissue healing are conserved albeit contextually modulated. This discovery propels the field into a new frontier, advocating for the exploration of shared regenerative targets that can be manipulated across diverse organ systems.

AD-NP1’s journey into clinical trials commenced recently with FDA approval of a Phase 1 safety study in human patients recovering from heart attacks. This milestone reflects the rigorous preclinical validation of the drug’s pharmacodynamics and safety profile. Building on these milestones, ongoing efforts at UCLA aim to extend these trials to include patients with progressive kidney disease, setting the stage for comprehensive evaluation and potential future clinical application.

Underlying this innovative research are substantial investments from the National Institutes of Health, California Institute of Regenerative Medicine, and the U.S. Department of Defense. This underscores the strategic importance and translational potential of regenerative medicine therapies in addressing chronic diseases that impose heavy societal burdens. The interdisciplinary collaboration among cardiovascular scientists, nephrologists, and molecular biologists at UCLA exemplifies the synergy needed to unlock complex biological processes for therapeutic gain.

In summation, the identification of ENPP1 as a metabolic gatekeeper that impedes tissue repair, combined with the development of AD-NP1 to neutralize its effects, represents a significant leap forward in regenerative medicine. The drug’s ability to foster organ regeneration by restoring metabolic and cellular homeostasis offers hope for millions afflicted by kidney disease and opens novel avenues for organ repair strategies. As clinical trials progress, the scientific community eagerly anticipates further validation of these findings, potentially heralding a new era where molecularly targeted therapies can substantially reverse organ damage and restore quality of life.

Subject of Research: Kidney regeneration, metabolic regulation of tissue repair, ENPP1 protein inhibition, monoclonal antibody therapy

Article Title: UCLA Researchers Discover Novel Role for ENPP1 Inhibition in Enhancing Kidney Repair via AD-NP1

News Publication Date: Not specified (based on provided content)

Web References: Cell Stem Cell Journal Article

Keywords: ENPP1, kidney injury, chronic kidney disease, tissue regeneration, monoclonal antibody, AD-NP1, metabolic signaling, renal repair, fibrosis, UCLA, regenerative medicine, Phase 1 clinical trial